| Title | Date | Affymetrix Appoints Gavin Wood as Executive Vice President and Chief Financial Officer| A seasoned financial leader with extensive international experience
SANTA CLARA, Calif.--(BUSINESS WIRE)--May. 20, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) today announced it has appointed Mr. Gavin Wood to the position of Executive Vice President and Chief Financial Officer. Mr. Wood joined Affymetrix in 2006 and served most recently as VP Finance, International Controller based in the United Kingdom.
Mr. Wood will report to President and Chief Executive Officer Frank Witney and will oversee ... |
| 05/20/13 | Affymetrix Reports 2013 First Quarter Results| SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 30, 2013--
Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results
for the three months ended March 31, 2013.
Results for the three months ended March 31, 2013:
Total revenue was $77.9 million, which included revenue from
eBioscience of $19.0 million.
GAAP net loss was $15.4 million, or $0.24 per diluted share, as
compared to a net loss of $4.2... |
| 04/30/13 | Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data Generated From FFPE Solid Tumor Samples for Accelerating Cancer Translational Research| SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 10, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) and BioDiscovery announce the availability of the Nexus for OncoScan® Software for analysis of whole genome copy number data generated from formalin-fixed, paraffin-embedded (FFPE) solid tumor samples using the OncoScan® FFPE Express 2.0 Service. Through a joint arrangement, this software, based on BioDiscovery's flagship Nexus Copy Number™, is available to customers who are analyzing data generated using this ... |
| 04/10/13 | Affymetrix Announces Preliminary Revenue for First Quarter 2013| SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 9, 2013--
Affymetrix, Inc. (Nasdaq: AFFX) today reported that based on preliminary
financial data, the Company expects total revenue of approximately $78
million for the first quarter of 2013, including revenue of
approximately $19 million from eBioscience. The Company expects to
report cash-on-hand of at least $38 million as of March 31, 2013.
“Our revenues for the first quarter were below expectations,... |
| 04/09/13 | Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Study of Genetic and Environmental Factors in Disease and Personalized Medicine| SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar. 22, 2013--
Affymetrix,
Inc. (NASDAQ: AFFX) today announced that it has signed a contract
with UK
Biobank to genotype 500,000 DNA samples donated by UK residents as
part of a prospective epidemiological study of complex diseases that are
of great relevance to public health. Affymetrix’ Axiom®
Genotyping Solution will be used to generate billions of
high-quality genotypes which will provide UK Bi... |
| 03/22/13 | Aqua Gen and Center for Integrative Genomics (CIGENE) Collaborate With Affymetrix on a Salmon Genotyping Array to Achieve the World’s First High-Density View of the Marker Patterns in the Atlantic Salmon| ÅS, Norway & SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar. 19, 2013--
Aqua
Gen, a member of the Erich Wesjohann (EW) Group GmBH and Center
for Integrative Genomics (CIGENE) at the Norwegian University of
Life Sciences (UMB) in collaboration with Affymetrix,
Inc. (NASDAQ: AFFX) announced today that they are the first to
genotype more than 900,000 markers per sample from the Atlantic salmon (Salmo
salar), thereby achieving the capability to imp... |
| 03/19/13 | Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider Increasing Accessibility for Bioinformatics in Genomic Research| SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar. 6, 2013-- Affymetrix, Inc. (NASDAQ:AFFX) announced a co-marketing agreement today naming GenoSplice, Inc. as its preferred data analysis service provider for the new GeneChip® Human Transcriptome Array 2.0, the most comprehensive microarray available for alternative splicing detection. GenoSplice, a leader in genomic data analysis and alternative splicing, has developed a dedicated expression analysis solution, EASANA®, including analysis for Affymetrix... |
| 03/06/13 | Affymetrix and DNA Link Sign Partnership for Forensic Test Development for Human Identification| SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 7, 2013-- Affymetrix, Inc. (NASDAQ: AFFX) and DNA Link, Inc., a Korean genomics-based biotechnology company, today announced that they have signed a Powered by AffymetrixTM (PbA) Program agreement in which DNA Link, Inc. obtains a worldwide license to develop and commercialize a forensic test for comprehensive human identification and other diagnostic tests using Affymetrix' microarray technology and the Korea FDA (KFDA) cleared GeneChip® System 3000Dx ... |
| 02/07/13 | Affymetrix to Webcast Presentation at the 2013 Leerink Swann Global Healthcare Conference| SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 5, 2013--
Affymetrix, Inc. (Nasdaq:AFFX) today announced that it will webcast the
Company’s presentation at the Leerink Swann Global Healthcare Conference
in New York City on Thursday, February 14, 2013. The live webcast is
scheduled to begin at 3:00 p.m. ET and will feature a corporate overview
and update by Tim Barabe, executive vice president and chief financial
officer.
A live webcast will... |
| 02/05/13 | Affymetrix Reports Fourth Quarter and Fiscal Year 2012 Results| SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 31, 2013--
Affymetrix, Inc., (NASDAQ: AFFX) today reported its operating results
for the three and twelve months ended December 31, 2012.
Results for the three months ended December 31, 2012:
Total revenue was $84.4 million, which excluding eBioscience of $18.1
million, represented a 2% increase from the fourth quarter of 2011.
GAAP net loss was $12.3 million, or... |
| 01/31/13 | Affymetrix Announces Preliminary Fourth Quarter Revenue of $84 Million and Implements Corporate Restructuring to Accelerate Path to Profitability|
Preliminary fourth quarter revenue of $84 million.
Restructuring expected to result in savings of approximately $25
million on an annualized basis
The Company prepaid entire senior debt principal of $9.6 million due
in 2013
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 8, 2013--
Affymetrix, Inc., (NASDAQ: AFFX) today announced that based on
preliminary financial data, the C... |
| 01/08/13 | Affymetrix to Webcast Presentation at the 31st Annual JP Morgan Healthcare Conference| SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 3, 2013--
Affymetrix, Inc. (Nasdaq:AFFX) today announced that it will webcast the
Company’s presentation at the 31st Annual JP Morgan Healthcare
Conference in San Francisco, California on Thursday, January 10, 2013.
The live webcast is scheduled to begin at 8:30 a.m. PT and will feature
a corporate overview by Dr. Frank Witney, president and chief executive
officer.
A live webcast will be avai... |
| 01/03/13 | Affymetrix Announces Redemption of 3.50% Senior Convertible Notes| SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 3, 2012--
Affymetrix, Inc., (NASDAQ: AFFX) today has given notice of its intention
to redeem all of the outstanding 3.50% Senior Convertible Notes due 2038
(CUSIP 00826TAG3) (the “Convertible Notes”) on January 15, 2013. As of
November 15, 2012, there was approximately $3.9 million aggregate
principal amount of the Convertible Notes outstanding. The Convertible
Notes will be redeemed at a redemption price of... |
| 12/03/12 | Affymetrix Announces Research Collaboration With Centre for Proteomic and Genomic Research (CPGR) in South Africa| SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 20, 2012-- Affymetrix, Inc. (NASDAQ: AFFX) today announced a research and service collaboration with the Centre for Proteomic and Genomic Research (CPGR) in South Africa. CPGR will provide gene expression and Axiom genotyping services to African researchers using GeneTitan® . The Affymetrix and CPGR partnership aims to enable high-throughput genomics research and personalized medicine projects across Africa.
The CPGR is a nonprofit organization funded... |
| 11/20/12 | Affymetrix Introduces Axiom® miRNA Target Site Genotyping Arrays| The only commercially available high-density, genome-wide genotyping solution for microRNAs and their mRNA target sites
SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 6, 2012-- Affymetrix, Inc. (NASDAQ:AFFX) introduces Axiom, the only high-density genotyping tools for genome-wide evaluation of microRNA (miRNA) target sites. These new arrays will enable comprehensive studies to elucidate how genomic variation in miRNA regulatory machinery influences gene expression and disease risk. It interrogates... |
| 11/06/12 |
|
